Geode Capital Management
ACOR

Geode Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Geode Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,335
Closed -$39.1K – 4827
2023
Q1 		$39.1K Sell
3,335
-48
-1% -$798 ﹤0.01% 4573
2022
Q4 		$51K Buy
3,383
+1,047
+45% +$12.2K ﹤0.01% 4588
2022
Q3 		$13K Hold
2,336
– – ﹤0.01% 4966
2022
Q2 		$21K Hold
2,336
– – ﹤0.01% 4920
2022
Q1 		$75K Hold
2,336
– – ﹤0.01% 4733
2021
Q4 		$111K Hold
2,336
– – ﹤0.01% 4699
2021
Q3 		$214K Sell
2,336
-1,342
-36% -$111K ﹤0.01% 4421
2021
Q2 		$350K Buy
3,678
+435
+13% +$38K ﹤0.01% 4097
2021
Q1 		$315K Sell
3,243
-84
-3% -$10.3K ﹤0.01% 3972
2020
Q4 		$283K Buy
3,327
+305
+10% +$28K ﹤0.01% 3777
2020
Q3 		$186K Sell
3,022
-19
-0.6% -$1.43K ﹤0.01% 3741
2020
Q2 		$268K Sell
3,041
-2,348
-44% -$248K ﹤0.01% 3580
2020
Q1 		$603K Sell
5,389
-367
-6% -$72.2K ﹤0.01% 3221
2019
Q4 		$1.41M Buy
5,756
+1,063
+23% +$268K ﹤0.01% 3145
2019
Q3 		$1.62M Sell
4,693
-620
-12% -$337K ﹤0.01% 3048
2019
Q2 		$4.89M Buy
5,313
+543
+11% +$667K ﹤0.01% 2409
2019
Q1 		$7.61M Buy
4,770
+279
+6% +$503K ﹤0.01% 2079
2018
Q4 		$8.4M Sell
4,491
-101
-2% -$220K ﹤0.01% 1890
2018
Q3 		$10.8M Buy
4,592
+418
+10% +$1.29M ﹤0.01% 1859
2018
Q2 		$14.4M Buy
4,174
+682
+20% +$2.09M ﹤0.01% 1591
2018
Q1 		$9.91M Buy
3,492
+75
+2% +$225K ﹤0.01% 1769
2017
Q4 		$8.79M Sell
3,417
-174
-5% -$495K ﹤0.01% 1839
2017
Q3 		$10.2M Sell
3,591
-194
-5% -$511K ﹤0.01% 1716
2017
Q2 		$8.95M Buy
3,785
+111
+3% +$220K ﹤0.01% 1737
2017
Q1 		$9.26M Buy
3,674
+276
+8% +$794K ﹤0.01% 1669
2016
Q4 		$7.67M Buy
3,398
+203
+6% +$483K ﹤0.01% 1770
2016
Q3 		$8M Buy
3,195
+174
+6% +$519K ﹤0.01% 1641
2016
Q2 		$9.24M Buy
3,021
+54
+2% +$176K 0.01% 1489
2016
Q1 		$9.41K Buy
2,967
+342
+13% +$1.42M 0.01% 1442
2015
Q4 		$13.5M Buy
2,625
+169
+7% +$739K 0.01% 1153
2015
Q3 		$7.81M Buy
2,456
+26
+1% +$101K ﹤0.01% 1524
2015
Q2 		$9.72M Buy
2,430
+204
+9% +$788K 0.01% 1430
2015
Q1 		$8.89M Sell
2,226
-130
-6% -$595K 0.01% 1474
2014
Q4 		$11.6M Buy
2,356
+29
+1% +$124K 0.01% 1212
2014
Q3 		$9.46M Buy
2,327
+168
+8% +$630K 0.01% 1298
2014
Q2 		$8.73M Buy
2,159
+320
+17% +$1.3M 0.01% 1405
2014
Q1 		$8.36M Buy
1,839
+121
+7% +$489K 0.01% 1380
2013
Q4 		$6.02M Buy
1,718
+170
+11% +$663K ﹤0.01% 1562
2013
Q3 		$6.37M Buy
1,548
+100
+7% +$431K 0.01% 1388
2013
Q2 		$5.73M Buy
+1,448
New +$5.96M 0.01% 1315

Other funds holding ACOR

DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Geode Capital Management's ACOR Position: Q2 2023 in Review

Geode Capital Management sold out of Acorda Therapeutics (ACOR) in Q2 2023, closing a stake of 3,335 shares — an estimated $39.1K sold.

Geode Capital Management first reported a position in ACOR in Q2 2013 and held it in 40 quarters. The position peaked at $14.4M in Q2 2018. 15 funds tracked by Wall St. Rank hold ACOR as of Q2 2023.

  • Geode Capital Management reported no remaining Acorda Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Geode Capital Management sold 3,335 Acorda Therapeutics shares in Q2 2023, an estimated $39.1K.
  • Geode Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 40 quarters.
  • Geode Capital Management's Acorda Therapeutics position peaked at $14.4M in Q2 2018.
  • 15 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.